Ribomic Inc.
Tokyo Stock Exchange 4591.T
Ribomic Inc. Current Liabilities for the year ending March 31, 2024
Ribomic Inc. Current Liabilities is NA for the year ending March 31, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
-
Ribomic Inc. Current Liabilities for the year ending March 31, 2021 was USD 1.06 M, a 29.06% change year over year.
-
Ribomic Inc. Current Liabilities for the year ending March 31, 2020 was USD 818.31 K.
Key data
| Date | Current Liabilities | Total Non-Current Liabilities | Shareholders' Equity | Long-Term Debt |
|---|
Market news
Loading...
Don’t Miss A Beat
Tokyo Stock Exchange: 4591.T
| CEO | Mr. Yoshikazu Nakamura Ph.D. |
| IPO Date | Sept. 25, 2014 |
| Location | Japan |
| Headquarters | Shirokanedai Usui Building |
| Employees | 24 |
| Sector | Health Care |
| Industries | |
Description
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.
Key trends
Past 5 years
StockViz Staff
February 10, 2025
Any question? Send us an email